MedTrace Logo

A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients

NCT03983382 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2026-05-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.

Conditions

Interventions

DIAGNOSTIC_TEST

Left Ventricular Ejection Fraction

LVEF assessment at baseline, 6 months, and 12 months

Sponsors & Collaborators

Principal Investigators

  • Anthony Yu, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-22
Primary Completion
2023-09-18
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03983382 on ClinicalTrials.gov